Chaccour C et al., 2025-12: The Mozambique arm of BOHEMIA found no reduction in childhood malaria incidence with monthly ivermectin MDA, in humans alone or in humans plus livestock; the authors attribute the null result partly to cyclone-related operational failure and low coverage.
the malaria infection incidence was comparable between all three arms with adjusted incidence rate ratio values of 0.99 (95% CI, 0.86-1.14, P > 0.9)
Chaccour C et al., 2025-12: The Mozambique arm of BOHEMIA found no reduction in childhood malaria incidence with monthly ivermectin MDA, in humans alone or in humans plus livestock; the authors attribute the null result partly to cyclone-related operational failure and low coverage. Open-label, assessor-masked cluster-randomized trial, Mopeia district, Zambezia province, Mozambique; planned 53 clusters per arm (1:1:1), 57 clusters lost to Cyclone Gombe, 22,724 participants from 100 clusters analysed; arms: ivermectin 400 micrograms/kg to humans monthly x3, the same plus injectable ivermectin 1% to pigs (300 micrograms/kg) and cattle (200 micrograms/kg), or albendazole 400 mg control. IRR 0.99 (0.86-1.14) human-only vs control and 1.05 (0.87-1.27) human+livestock vs control; severe AE IRR 1.29 (0.62-2.68). All authors declare no competing interests. The authors state the trial did not meet implementation goals (low coverage, displaced populations, delayed start). Same BOHEMIA consortium as IVE-16; the Mozambique abstract does not state a funder, so none is asserted here. Study type: randomized trial.
